EP1402262A4 - Map3ks utiles en tant que modificateurs de la voie p53 et methodes d'utilisation - Google Patents

Map3ks utiles en tant que modificateurs de la voie p53 et methodes d'utilisation

Info

Publication number
EP1402262A4
EP1402262A4 EP02741809A EP02741809A EP1402262A4 EP 1402262 A4 EP1402262 A4 EP 1402262A4 EP 02741809 A EP02741809 A EP 02741809A EP 02741809 A EP02741809 A EP 02741809A EP 1402262 A4 EP1402262 A4 EP 1402262A4
Authority
EP
European Patent Office
Prior art keywords
map3ks
modifier
pathway
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02741809A
Other languages
German (de)
English (en)
Other versions
EP1402262A2 (fr
Inventor
Lori Friedman
Gregory D Plowman
Marcia Belvin
Helen Francis-Lang
Danxi Li
Roel P Funke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of EP1402262A2 publication Critical patent/EP1402262A2/fr
Publication of EP1402262A4 publication Critical patent/EP1402262A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP02741809A 2001-06-05 2002-06-03 Map3ks utiles en tant que modificateurs de la voie p53 et methodes d'utilisation Withdrawn EP1402262A4 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US29607601P 2001-06-05 2001-06-05
US296076P 2001-06-05
US32860501P 2001-10-10 2001-10-10
US328605P 2001-10-10
US35725302P 2002-02-15 2002-02-15
US357253P 2002-02-15
US36119602P 2002-03-01 2002-03-01
US361196P 2002-03-01
PCT/US2002/017457 WO2002098889A2 (fr) 2001-06-05 2002-06-03 Map3ks utiles en tant que modificateurs de la voie p53 et methodes d'utilisation

Publications (2)

Publication Number Publication Date
EP1402262A2 EP1402262A2 (fr) 2004-03-31
EP1402262A4 true EP1402262A4 (fr) 2005-05-11

Family

ID=27501675

Family Applications (2)

Application Number Title Priority Date Filing Date
EP02741809A Withdrawn EP1402262A4 (fr) 2001-06-05 2002-06-03 Map3ks utiles en tant que modificateurs de la voie p53 et methodes d'utilisation
EP02732039A Withdrawn EP1402051A4 (fr) 2001-06-05 2002-06-03 Lce utilises comme modificateurs de la voie p53 et procede d'utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP02732039A Withdrawn EP1402051A4 (fr) 2001-06-05 2002-06-03 Lce utilises comme modificateurs de la voie p53 et procede d'utilisation

Country Status (5)

Country Link
EP (2) EP1402262A4 (fr)
JP (2) JP2005514906A (fr)
AU (1) AU2002314887A1 (fr)
CA (2) CA2448112A1 (fr)
WO (4) WO2002098891A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012233044B2 (en) * 2002-11-22 2015-09-03 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP2006517788A (ja) * 2002-12-20 2006-08-03 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １５９８６、２１８８、２０７４３、９１４８、９１５１、９７９１、４４２５２、１４１８４、４２４６１、８２０４、７９７０、２５５５２、２１６５７、２６４９２、２４１１、１５０８８、１９０５、２８８９９、６３３８０、３３９３５、１０４８０、１２６８６、２５５０１、１７６９４、１５７０１、５３０６２、４９９０８、２１６１２、３８９４９、６２１６、４６８６３、９２３５、２２０１、６９８５、９８８３、１２２３８、１８０５７、２１６１７、３９２２８、４９９２８、５４４７６、６２１１３、６４３１６、１２２６４、３２３６２、５８１９８、２８８７、３２０５、８５５７、９６００、９６９３、４４８６７、５３０５８、５５５５６、５７６５８、２２０８、１０２５２、１０３０２、１４２１８、３３８７７、１０３１７、１０４８５、２５９６４、１４８１５、１３６３、１３９７、１４８２７、２１７０８、３８０１、６４６９８、２１７９または１３２４９を使用する癌を処置するための方法および組成物
DE10316701A1 (de) * 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
EP1657311A4 (fr) * 2003-07-11 2006-10-11 Banyu Pharma Co Ltd Methode d'evaluation de compose efficace dans le traitement de l'obesite
US20070087984A1 (en) * 2003-09-04 2007-04-19 Xiuyuan Hu Method of identifying agents that inhibit the growth of cancer cells
WO2005083425A2 (fr) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Agents de diagnostic et de therapie destines aux maladies associees a la proteine kinase 13 activee par un mitogene (map3k13)
US7622367B1 (en) 2004-06-04 2009-11-24 The Board Of Trustees Of The University Of Illinois Methods and devices for fabricating and assembling printable semiconductor elements
KR101610885B1 (ko) 2007-01-17 2016-04-08 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 프린팅­기반 어셈블리에 의해 제조되는 광학 시스템
KR101706915B1 (ko) 2009-05-12 2017-02-15 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 변형가능 및 반투과 디스플레이를 위한 초박형, 미세구조 무기발광다이오드의 인쇄 어셈블리
WO2012097163A1 (fr) 2011-01-14 2012-07-19 The Board Of Trustees Of The University Of Illinois Réseau de composants optiques ayant une courbure réglable
US9765934B2 (en) 2011-05-16 2017-09-19 The Board Of Trustees Of The University Of Illinois Thermally managed LED arrays assembled by printing
WO2012167096A2 (fr) 2011-06-03 2012-12-06 The Board Of Trustees Of The University Of Illinois Réseau d'électrodes de surface conformables, multiplexées de manière active et à haute densité, pour un interfaçage avec le cerveau
JP6231489B2 (ja) 2011-12-01 2017-11-15 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ プログラム可能な変化を被るように設計された遷移デバイス
CN114181944B (zh) * 2020-09-14 2023-10-03 中国科学院动物研究所 突变基因及构建短肢性侏儒症小型猪模型的方法和用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024159A1 (fr) * 1993-04-15 1994-10-27 National Jewish Center For Immunology And Respiratory Medicine Procede et produit de regulation de la reactivite cellulaire a des signaux externes
WO1999041385A1 (fr) * 1998-02-13 1999-08-19 Cadus Pharmaceutical Corporation Proteines mekk1 et leurs fragments destines a etre utilises dans la regulation d'une apoptose
WO1999047686A2 (fr) * 1998-03-16 1999-09-23 Cadus Pharmaceutical Corporation Proteines humaines mekk, molecules d'acides nucleiques et procedes d'utilisation correspondants
WO2002014355A2 (fr) * 2000-08-11 2002-02-21 Merck Patent Gmbh Nouvelles protéines mekk
WO2002096943A1 (fr) * 2001-05-25 2002-12-05 Asahi Kasei Kabushiki Kaisha Genes activant le stat6
WO2003091419A2 (fr) * 2002-04-24 2003-11-06 Incyte Corporation Kinases et phosphatases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014485A1 (fr) * 1991-02-22 1992-09-03 Amrad Corporation Limited Procede de diagnostic et de traitement de maladies associees a l'autoantigene de decarboxylase d'acide glutamique
US5554523A (en) * 1994-03-01 1996-09-10 Children's Hospital Of Philadelphia Nucleic acid sequences encoding human leucine-zipper protein-kinase
WO2001034643A1 (fr) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 24 proteines humaines secretees
CA2365096A1 (fr) * 1999-03-18 2000-09-21 The University Of Bristol Elongase d'acides gras polyinsatures tires de caenorhabiditis elegans
EP1173566A2 (fr) * 1999-04-23 2002-01-23 Incyte Genomics, Inc. Proteines humaines associees aux membranes
AU6418000A (en) * 1999-07-22 2001-02-13 University Of British Columbia, The A plant long chain fatty acid biosynthetic enzyme
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001270045A1 (en) * 2000-06-20 2002-01-02 Incyte Genomics, Inc. Secreted proteins
US7297523B2 (en) * 2000-11-29 2007-11-20 Xenon Pharmaceuticals Inc. Human elongase genes and uses thereof
EP1432801A2 (fr) * 2001-02-06 2004-06-30 Incyte Genomics, Inc. Recepteurs et proteines associees a une membrane
WO2002062974A2 (fr) * 2001-02-08 2002-08-15 Bayer Aktiengesellschaft Regulation de la proteine humaine elongase hselo1
AU2002250900A1 (en) * 2001-02-08 2002-08-19 Bayer Aktiengesellschaft Regulation of human elongase hselo1-like protein

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024159A1 (fr) * 1993-04-15 1994-10-27 National Jewish Center For Immunology And Respiratory Medicine Procede et produit de regulation de la reactivite cellulaire a des signaux externes
WO1999041385A1 (fr) * 1998-02-13 1999-08-19 Cadus Pharmaceutical Corporation Proteines mekk1 et leurs fragments destines a etre utilises dans la regulation d'une apoptose
WO1999047686A2 (fr) * 1998-03-16 1999-09-23 Cadus Pharmaceutical Corporation Proteines humaines mekk, molecules d'acides nucleiques et procedes d'utilisation correspondants
WO2002014355A2 (fr) * 2000-08-11 2002-02-21 Merck Patent Gmbh Nouvelles protéines mekk
WO2002096943A1 (fr) * 2001-05-25 2002-12-05 Asahi Kasei Kabushiki Kaisha Genes activant le stat6
WO2003091419A2 (fr) * 2002-04-24 2003-11-06 Incyte Corporation Kinases et phosphatases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AGARWAL M L ET AL: "Regulation of p53 expression by the RAS-MAP kinase pathway.", ONCOGENE. 3 MAY 2001, vol. 20, no. 20, 3 May 2001 (2001-05-03), pages 2527 - 2536, XP002306482, ISSN: 0950-9232 *
DATABASE WPI Section Ch Week 200313, Derwent World Patents Index; Class B04, AN 2003-140442, XP002306484 *
LEE S W ET AL: "Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 18 JUL 2000, vol. 97, no. 15, 18 July 2000 (2000-07-18), pages 8302 - 8305, XP002306483, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2002099068A2 (fr) 2002-12-12
WO2002098891A3 (fr) 2003-05-30
EP1402262A2 (fr) 2004-03-31
WO2002098889A3 (fr) 2003-03-27
EP1402051A2 (fr) 2004-03-31
WO2002098891A2 (fr) 2002-12-12
JP2005514906A (ja) 2005-05-26
WO2002098468A1 (fr) 2002-12-12
AU2002314887A1 (en) 2002-12-16
JP2004532638A (ja) 2004-10-28
WO2002099068A3 (fr) 2003-12-04
EP1402051A4 (fr) 2005-08-17
CA2448112A1 (fr) 2002-12-12
WO2002098889A2 (fr) 2002-12-12
CA2449479A1 (fr) 2002-12-12

Similar Documents

Publication Publication Date Title
EP1572890A4 (fr) Slc7s utilises en tant que modificateurs de la voie p53 et procedes d'utilisation correspondants
EP1421384A4 (fr) Hprp4 en tant que modificateurs de la voie de passage p53 leurs et methodes d'utilisation
AU2003224638A8 (en) Pdpk1s as modifiers of the p53 pathway and methods of use
HK1078266A1 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
AU2002219135A1 (en) Substituted 2-anilino-benzimidazoles and the use thereof as NHE-inhibitors
EP1402262A4 (fr) Map3ks utiles en tant que modificateurs de la voie p53 et methodes d'utilisation
MXPA03007126A (es) Composiciones parasiticidas y metodos de uso.
AU2002239933A1 (en) Antineoplastic polyalkoxyalkylsiloxanes and methods of use thereof
AU2002337916A1 (en) Modifier of the p53 pathway and methods of use
EP1418194A4 (fr) Polyalkyleneimine modifie et ses procedes d'utilisation
AU2002343100A1 (en) The use of metal-chelating adsorbents
AU2001233588A1 (en) New toralactone and its derivation and the use of decreasing blood-fat and losing weight
AU2002256967A1 (en) Treating or reducing the risk of cardiovascular disease
AU2002360586A8 (en) Flj1115 as modifier of the apaf-1 pathway and methods of use
AU2003303094A8 (en) Mat2as as modifiers of the p53 pathway and methods of use
AU2002357817A8 (en) Klcs as modifiers of the p53 pathway and methods of use
AU2002312283A1 (en) Srpks as modifiers of the p53 pathway and methods of use
AU2002303947A1 (en) Pecis as modifiers of the p53 pathway and methods of use
AU2002345486A1 (en) Slc13as as modifiers of the p53 pathway and methods of use
AU2002303951A1 (en) Glras as modifiers of the p53 pathway and methods of use
AU2002314874A1 (en) Modifiers of the p53 pathway and methods of use
AU2002332130A1 (en) Msrebps as modifiers of the srebp pathway and methods of use
AU2002361654A1 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2002333371A1 (en) Novel 4-aminofuropyrimidines and the use thereof
AU2003278811A8 (en) Ldlrs as modifiers of the p53 pathway and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031219

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7G 01N 33/50 B

Ipc: 7A 61K 38/00 B

Ipc: 7G 01N 33/53 A

A4 Supplementary search report drawn up and despatched

Effective date: 20050321

17Q First examination report despatched

Effective date: 20050504

17Q First examination report despatched

Effective date: 20050504

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070402